Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Bone marrow-derived cells and the vasculature in diabetes: from biomarker to treatment?

Bone marrow-derived cells and the vasculature in diabetes: from biomarker to treatment? Diabetologia (2007) 50:2033–2035 DOI 10.1007/s00125-007-0773-2 COMMENTARY Bone marrow-derived cells and the vasculature in diabetes: from biomarker to treatment? N. A. Hanley Received: 25 June 2007 /Accepted: 27 June 2007 /Published online: 26 July 2007 Springer-Verlag 2007 In early June 2007, a search for ‘stem cells’ and ‘diabetes’ autologous haematopoietic stem cell transplantation can in PubMed retrieved 549 articles. The breakdown was alleviate immune destruction in new-onset type 1 diabetes rather skewed: 497 were published after the year 2000, [12], and bone marrow-derived (BMD) cells downstream of whilst a mere 52 were published earlier. This difference their founder stem cell population have been recognised to largely reflects the first description of human embryonic serve as endothelial progenitor cells (EPCs). EPCs raise the stem cells (ESCs) in 1998 [1]. Nearly a decade has passed prospect of extending replacement or regeneration to the since then, and stem cell research has diversified. Human treatment of diabetic vascular complications. Even so, ESCs for engineering transplantable beta cells ex vivo have the EPC remains controversial: What is its phenotype? attracted great interest in both the commercial and academic What does it signify? and, most presciently, What does it sectors, but have yet to deliver in http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Diabetologia Springer Journals

Bone marrow-derived cells and the vasculature in diabetes: from biomarker to treatment?

Diabetologia , Volume 50 (10) – Oct 1, 2007

Loading next page...
 
/lp/springer-journals/bone-marrow-derived-cells-and-the-vasculature-in-diabetes-from-T2n3qQ2pwy

References (31)

Publisher
Springer Journals
Copyright
Copyright © 2007 by Springer-Verlag
Subject
Medicine & Public Health; Human Physiology ; Metabolic Diseases ; Internal Medicine
ISSN
0012-186X
eISSN
1432-0428
DOI
10.1007/s00125-007-0773-2
pmid
17653690
Publisher site
See Article on Publisher Site

Abstract

Diabetologia (2007) 50:2033–2035 DOI 10.1007/s00125-007-0773-2 COMMENTARY Bone marrow-derived cells and the vasculature in diabetes: from biomarker to treatment? N. A. Hanley Received: 25 June 2007 /Accepted: 27 June 2007 /Published online: 26 July 2007 Springer-Verlag 2007 In early June 2007, a search for ‘stem cells’ and ‘diabetes’ autologous haematopoietic stem cell transplantation can in PubMed retrieved 549 articles. The breakdown was alleviate immune destruction in new-onset type 1 diabetes rather skewed: 497 were published after the year 2000, [12], and bone marrow-derived (BMD) cells downstream of whilst a mere 52 were published earlier. This difference their founder stem cell population have been recognised to largely reflects the first description of human embryonic serve as endothelial progenitor cells (EPCs). EPCs raise the stem cells (ESCs) in 1998 [1]. Nearly a decade has passed prospect of extending replacement or regeneration to the since then, and stem cell research has diversified. Human treatment of diabetic vascular complications. Even so, ESCs for engineering transplantable beta cells ex vivo have the EPC remains controversial: What is its phenotype? attracted great interest in both the commercial and academic What does it signify? and, most presciently, What does it sectors, but have yet to deliver in

Journal

DiabetologiaSpringer Journals

Published: Oct 1, 2007

There are no references for this article.